Development trends for human monoclonal antibody therapeutics

@article{Nelson2010DevelopmentTF,
  title={Development trends for human monoclonal antibody therapeutics},
  author={Aaron L. Nelson and Eugen Dhimolea and Janice M Reichert},
  journal={Nature Reviews Drug Discovery},
  year={2010},
  volume={9},
  pages={767-774}
}
Fully human monoclonal antibodies (mAbs) are a promising and rapidly growing category of targeted therapeutic agents. The first such agents were developed during the 1980s, but none achieved clinical or commercial success. Advances in technology to generate the molecules for study — in particular, transgenic mice and yeast or phage display — renewed interest in the development of human mAbs during the 1990s. In 2002, adalimumab became the first human mAb to be approved by the US Food and Drug… 
Phage display-derived human antibodies in clinical development and therapy
TLDR
A comprehensive overview about phage display-derived antibodies that are approved for therapy or in clinical development is provided and a selection of these antibodies is described in more detail to demonstrate different aspects of thephage display technology and its development over the last 25 years.
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
TLDR
The rationale beyond dose selection in phase II and III trials of mAbs is often unclear in published articles and not based on FIHT data.
Trastuzumab-Resistance and Breast Cancer
TLDR
It has emerged that the levels of antigen expression are not the only determinant of the patient response to monoclonal antibody therapies and that better understanding of the mechanisms of resistance to monOClonal antibodies in different patient subgroups has a potential to improve the effectiveness of the monoconal antibody treatment.
The development of potential antibody-based therapies for myeloma.
TLDR
The development pipeline for naked antibodies and antibody-drug conjugates for myeloma is reviewed, and it is optimistic that the first FDA-approved antibody therapeutic(s) for this disease will emerge in the near future.
Antibodies in oncology.
TLDR
An overview of mAbs approved for use in clinical oncology and those currently in clinical development is provided and the mechanisms of action of anti-cancer mAbs are discussed, as well as the antigen targets recognised by these antibodies.
Frontier of therapeutic antibody discovery: The challenges and how to face them.
TLDR
The in silico and T-cell response approaches identify the potential for immunogenicity; however, one needs contingency plans for emergence of anti-product antibody response for clinical trials.
Licensed monoclonal antibodies and associated challenges.
TLDR
This review underscores the associated challenges of mAbs, approved by FDA from 2007-2014 and recommends that patients, physicians, biopharmaceutical companies, and researchers should keep in touch to highlight and resolve antibody-based adverse events.
Frontiers of monoclonal antibodies: Applications in medical practices.
TLDR
The history of mAb generation and the innovative technological applications of mAbs that has advanced in clinical practices is reviewed and compared to conventional drugs, since mAbs use as pharmacologic iotas have specific physical features and modes of action, they should be considered as a discrete therapeutic category.
The history of monoclonal antibody development – Progress, remaining challenges and future innovations
  • J. Liu
  • Medicine
    Annals of medicine and surgery
  • 2014
TLDR
The history of monoclonal antibody development is reviewed – how it has increasingly moved away from using laborious animal models to a more effective phage display system, some of the major drawbacks from a clinical and economical point of view and future innovations that are currently being researched to maximise their effectiveness for future clinical use.
Discovery Process for Antibody-Based Therapeutics
TLDR
An overview of immunogenicity, a unique challenge for protein-based therapeutics, is provided and a case study is included to illustrate the discovery process for bapineuzumab, a humanized anti-amyloid beta monoclonal antibody currently in Phase III clinical trials for the treatment of Alzheimer’s disease.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Antibodies to watch in 2010
TLDR
This overview of the 26 mAbs provides a brief description of the background and the on-going Phase 3 studies of each mAb, and will serve as a baseline against which future progress can be measured.
Monoclonal antibodies as innovative therapeutics.
  • J. Reichert
  • Medicine
    Current pharmaceutical biotechnology
  • 2008
Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in clinical development because of their versatility as therapeutic agents. While traditionally associated with the
Human antibodies from transgenic animals
  • N. Lonberg
  • Biology, Medicine
    Nature Biotechnology
  • 2005
TLDR
It may be possible to extend this technology beyond rodents and use transgenic farm animals to directly generate and produce human sequence polyclonal sera, and to fully validate this technology as a drug discovery tool.
The immunogenicity of humanized and fully human antibodies
TLDR
It is proposed that immunogenicity will always be present in some antibody molecules due to the nature of the antigen-specific combining sites and modifications to reduce immunogenic potential will be centered on the affinity-determining regions.
Human monoclonal antibody production. Current status and future prospects.
TLDR
The development of human monoclonal antibody technology has been a slow, laborious and often unrewarding exercise, but in spite of the many problems encountered to date work has continued unabated, sustained by the widely held belief that this technology would result in improved diagnostics and therapeutics and would increase the understanding of human biology.
Role of panitumumab in the management of metastatic colorectal cancer.
TLDR
Panitumumab is the first fully human monoclonal antibody directed against the epidermal growth factor receptor in clinical use and has proven to be very well tolerated alone and in combination with other cytotoxic chemotherapeutic agents.
Development trends for monoclonal antibody cancer therapeutics
TLDR
Trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980 are overviewed with the aim of informing future research and development for this class of therapeutics.
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
TLDR
Transgenic mice that express human IgM, IgG and Igκ in the absence of mouse IgM or Igκ are developed that contain human sequence transgenes that undergo V(D)J joining, heavy-chain class switching, and somatic mutation to generate a repertoire of human sequence immunoglobulins.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201
TLDR
It is concluded that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis.
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.
  • L. Green
  • Biology, Medicine
    Journal of immunological methods
  • 1999
TLDR
The utility of XenoMouse strains for the generation of large panels of high-affinity, fully human mAbs can be made available to researchers in the academic and private sectors, and should accelerate the development and application of mAbs as therapeutics for human disease.
...
1
2
3
4
5
...